, recherche d'anticorps anti-plaquette avec l'anticorps monoclonal anti-GpIa/IIa en présence de MP est négatif

, Abréviations : A.FOL : acide folinique ; DXM : dexamethasone ; IRINO : irinotecan ; MAIPA : Monoclonal Antibody-specific Immobilization of

, MP : méthylprednisolone ; OXA : oxaliplatine ; ODS : ondensetron ; 5-FU : 5-Fluorouracile. BIBLIOGRAPHIE 1. Jobin F. L'hémostase. Presses Université Laval, Platelet Antigen assay, 1995.

R. H. Aster and D. W. Bougie, Drug-induced immune thrombocytopenia, N. Engl. J. Med, vol.357, issue.6, pp.580-587, 2007.

C. Mueller-eckhardt and A. Salama, Drug-induced immune cytopenias: a unifying pathogenetic concept with special emphasis on the role of drug metabolites, Transfus Med Rev, vol.4, issue.1, pp.69-77, 1990.

N. R. Shulman and D. M. Reid, Mechanisms of drug-induced immunologically mediated cytopenias, Transfus Med Rev, vol.7, issue.4, pp.215-229, 1993.

R. H. Aster, Drug-induced immune cytopenias, Toxicology, vol.209, issue.2, pp.149-153, 2005.

R. H. Aster, Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors, Chest, vol.127, issue.2, pp.53-59, 2005.

J. E. Tcheng, D. J. Kereiakes, and A. M. Lincoff, Abciximab readministration: results of the ReoPro Readministration Registry, Circulation, vol.104, issue.8, pp.870-875, 2001.

B. R. Curtis, A. Divgi, M. Garritty, and R. H. Aster, Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug, J. Thromb. Haemost, vol.2, issue.6, pp.985-992, 2004.

B. R. Curtis, J. Swyers, A. Divgi, J. G. Mcfarland, and R. H. Aster, Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets, Blood, vol.99, issue.6, pp.2054-2059, 2002.

S. F. Garner, K. Campbell, and G. Smith, Teicoplanin-dependent antibodies: detection and characterization, Br. J. Haematol, vol.129, issue.2, pp.279-281, 2005.

D. W. Bougie, P. R. Wilker, and R. H. Aster, Patients with quinine-induced immune thrombocytopenia have both "drug-dependent" and "drug-specific" antibodies, Blood, vol.108, issue.3, pp.922-927, 2006.

R. H. Aster, Can drugs cause autoimmune thrombocytopenic purpura?, Semin. Hematol, vol.37, issue.3, pp.229-238, 2000.

Z. Q. Li, W. Liu, and K. S. Park, Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody, Blood, vol.99, issue.4, pp.1230-1236, 2002.

G. M. Arepally and T. L. Ortel, Clinical practice. Heparin-induced thrombocytopenia

. Engl, J. Med, vol.355, issue.8, pp.809-817, 2006.

G. M. Arepally, Heparin-induced thrombocytopenia, Blood, vol.129, issue.21, pp.2864-2872, 2017.

T. A. Rousan, I. T. Aldoss, and B. D. Cowley, Recurrent acute thrombocytopenia in the hospitalized patient: sepsis, DIC, HIT, or antibiotic-induced thrombocytopenia, Am. J. Hematol, vol.85, issue.1, pp.71-74, 2010.

A. J. Neylon, P. Saunders, and M. R. Howard, Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients, 18. van den Bemt PMLA, Meyboom RHB, Egberts ACG. Drug-induced immune thrombocytopenia. Drug Saf, vol.122, issue.6, pp.1243-1252, 2003.

U. Pedersen-bjergaard, M. Andersen, P. B. Hansen, U. Pedersen-bjergaard, M. Andersen et al., Drug-induced thrombocytopenia: clinical data on 309 cases and the effect of corticosteroid therapy, Eur. J. Clin. Pharmacol, vol.54, issue.9, pp.183-189, 1997.

U. Pedersen-bjergaard, M. Andersen, and P. B. Hansen, Thrombocytopenia induced by noncytotoxic drugs in Denmark 1968-91, J. Intern. Med, vol.239, issue.6, pp.509-515, 1996.

L. E. Böttiger and B. Böttiger, Incidence and cause of aplastic anemia, hemolytic anemia, agranulocytosis and thrombocytopenia, Acta Med Scand, vol.210, issue.6, pp.475-479, 1981.

D. A. Danielson, S. W. Douglas, P. Herzog, H. Jick, and J. B. Porter, Drug-induced blood disorders, JAMA, vol.252, issue.23, pp.3257-3260, 1984.

D. W. Kaufman, J. P. Kelly, and C. B. Johannes, Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study, Blood, vol.82, issue.9, pp.1749-1757, 1986.

J. N. George, G. E. Raskob, and S. R. Shah, Drug-induced thrombocytopenia: a systematic review of published case reports, Ann. Intern. Med, vol.129, issue.11, pp.886-890, 1998.

D. M. Arnold, I. Nazi, and T. E. Warkentin, Approach to the diagnosis and management of drug-induced immune thrombocytopenia, Transfus Med Rev, vol.27, issue.3, pp.137-145, 2013.

V. Drygalski, A. Curtis, B. R. Bougie, and D. W. , Vancomycin-induced immune thrombocytopenia, N. Engl. J. Med, vol.356, issue.9, pp.904-910, 2007.

R. H. Aster, B. R. Curtis, J. G. Mcfarland, and D. W. Bougie, Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management, J. Thromb. Haemost, vol.7, issue.6, pp.911-918, 2009.

J. N. George and R. H. Aster, Drug-induced thrombocytopenia: pathogenesis, evaluation, and management, Hematology Am Soc Hematol Educ Program, pp.153-158, 2009.

B. R. Curtis, J. Kaliszewski, and M. B. Marques, Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin, Am. J. Hematol, vol.81, issue.3, pp.193-198, 2006.

J. B. Ray, W. F. Brereton, and F. R. Nullet, Intravenous immune globulin for the treatment of presumed quinidine-induced thrombocytopenia, DICP, vol.24, issue.7-8, pp.693-695, 1990.

O. Pourrat, G. Touchard, and R. Robert, A kidney biopsy is clearly mandatory to confirm the indication of plasma exchanges in adult haemolytic uraemic syndrome, Ann Med Interne, vol.145, issue.5, pp.369-372, 1994.

K. Bencardino, G. Mauri, and A. Amatu, Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study, Clin Colorectal Cancer, vol.15, issue.3, pp.213-221, 2016.

G. Colucci, V. Gebbia, and G. Paoletti, Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale, J. Clin. Oncol, vol.23, issue.22, pp.4866-4875, 2005.

M. A. Graham, G. F. Lockwood, and D. Greenslade, Clinical pharmacokinetics of oxaliplatin: a critical review, Cancer Chemother. Pharmacol, vol.6, issue.4, pp.925-927, 2000.

M. A. Bautista, W. T. Stevens, and C. Chen, Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature, J Hematol Oncol, vol.3, issue.7, pp.1453-1459, 2010.

G. U. Erdem, M. Dogan, N. S. Demirci, and N. Zengin, Oxaliplatin-induced acute thrombocytopenia, J Cancer Res Ther, vol.12, issue.2, pp.509-514, 2016.

J. Desrame, H. Broustet, D. De-tailly, P. Girard, D. Saissy et al., Oxaliplatin-induced haemolytic anaemia, Lancet, vol.354, issue.9185, pp.1179-1180, 1999.

B. M. Taleghani, O. Meyer, and S. Fontana, Oxaliplatin-induced immune pancytopenia, Transfusion, vol.45, issue.5, pp.704-708, 2005.

F. Cobo, D. Celis, G. Pereira, and A. , Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature, Anticancer Drugs, vol.18, issue.8, pp.973-976, 2007.

P. Arndt, G. Garratty, I. E. Bolger, M. Lu, and Q. , Positive direct and indirect antiglobulin tests associated with oxaliplatin can be due to drug antibody and/or drug-induced nonimmunologic protein adsorption, Transfusion, vol.49, issue.4, pp.711-718, 2009.

H. Quack, L. Erpenbeck, and H. A. Wolff, Oxaliplatin-Induced Leukocytoclastic Vasculitis under Adjuvant Chemotherapy for Colorectal Cancer: Two Cases of a Rare Adverse Event, Case Rep Oncol, vol.6, issue.3, pp.609-615, 2013.

S. A. Curtis, B. R. Curtis, and A. I. Lee, A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia, Hematology, vol.23, issue.7, pp.429-432, 2018.

B. Royer, K. Lee, and B. Gruson, Methylprednisolone-induced immune thrombocytopenia, Blood, vol.115, issue.26, pp.5431-5432, 2010.

V. Kiefel, S. Santoso, M. Weisheit, and C. Müeller-eckhardt, Monoclonal antibody--specific immobilization of platelet antigens (MAIPA): a new tool for the identification of plateletreactive antibodies, Blood, vol.70, issue.6, pp.1722-1726, 1987.

F. Delbos, G. Bertrand, and L. Croisille, Fetal and neonatal alloimmune thrombocytopenia: predictive factors of intracranial hemorrhage, Transfusion, vol.56, issue.1, pp.59-66, 2016.

V. Kiefel, The MAIPA assay and its applications in immunohaematology, Transfus Med, vol.2, issue.3, pp.181-188, 1992.

C. Visco, M. Ruggeri, L. Evangelista, and M. , Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia, Blood, vol.111, issue.3, pp.1110-1116, 2008.

A. Aussy, O. Boyer, and N. Cordel, Dermatomyositis and Immune-Mediated Necrotizing Myopathies: A Window on, Autoimmunity and Cancer. Front Immunol, vol.8, p.992, 2017.

S. Bose, E. Wurm, M. J. Popovich, and B. J. Silver, Drug-induced immune-mediated thrombocytopenia in the intensive care unit, J Clin Anesth, vol.27, issue.7, pp.602-605, 2015.

A. Anand and H. Chauhan, Piperacillin and vancomycin induced severe thrombocytopenia in a hospitalized patient, Platelets, vol.22, issue.4, pp.294-301, 2011.

B. R. Curtis, Y. Hsu, and N. Podoltsev, Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies, Blood, vol.131, issue.13, pp.1486-1489, 2018.

, Abréviations : DX : dexamethasone ; LE : leucovorine ou acide folinique ; OX : oxaliplatine

I. Ir and . Interprétation, Les tests de MAIPA réalisés chez le premier patient (A) mettent en évidence des anticorps anti-GpII/IIIa dépendant de la dexamethasone et de l'acide folinique ainsi que des anticorps anti-GPIb/IX dépendant de l'oxaliplatine. Les tests de MAIPA réalisés chez le second patient (B) mettent en évidence des anticorps anti-GpIIb

, Abréviations : DX : dexamethasone ; LE : leucovorine ou acide folinique ; OX : oxaliplatine

I. Ir and . Interprétation, Les tests d'adsorption réalisés chez le premier patient (A) en présence de